Mostrar el registro sencillo del ítem
dc.contributor.author | Campos, Javier | |
dc.contributor.author | Pacheco, Rodrigo | |
dc.date.accessioned | 2024-09-26T00:28:55Z | |
dc.date.available | 2024-09-26T00:28:55Z | |
dc.date.issued | 2020-12 | |
dc.identifier.issn | 1863-2297 | |
dc.identifier.uri | https://repositorio.uss.cl/handle/uss/12292 | |
dc.description | Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. | |
dc.description.abstract | The renin-angiotensin system (RAS) is a fundamental regulator of blood pressure and has emerged as an important player in the control of inflammatory processes. Accordingly, imbalance on RAS components either systemically or locally might trigger the development of inflammatory disorders by affecting immune cells. At the same time, alterations in the dopaminergic system have been consistently involved in the physiopathology of inflammatory disorders. Accordingly, the interaction between the RAS and the dopaminergic system has been studied in the context of inflammation of the central nervous system (CNS), kidney, and intestine, where they exert antagonistic actions in the regulation of the immune system. In this review, we summarized, integrated, and discussed the cross talk of the dopaminergic system and the RAS in the regulation of inflammatory pathologies, including neurodegenerative disorders, such as Parkinson’s disease. We analyzed the molecular mechanisms underlying the interaction between both systems in the CNS and in systemic pathologies. Moreover, we also analyzed the impact of the commensal microbiota in the regulation of RAS and dopaminergic system and how it is involved in inflammatory disorders. Furthermore, we summarized the therapeutic approaches that have yielded positive results in preclinical or clinical studies regarding the use of drugs targeting the RAS and dopaminergic system for the treatment of inflammatory conditions. Further understanding of the molecular and cellular regulation of the RAS-dopaminergic cross talk should allow the formulation of new therapies consisting of novel drugs and/or repurposing already existing drugs, alone or in combination, for the treatment of inflammatory disorders. | en |
dc.language.iso | eng | |
dc.relation.ispartof | vol. 42 Issue: no. 6 Pages: 681-696 | |
dc.source | Seminars in Immunopathology | |
dc.title | Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation | en |
dc.type | Artículo de revisión | |
dc.identifier.doi | 10.1007/s00281-020-00819-8 | |
dc.publisher.department | Facultad de Medicina y Ciencia |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |